V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
R
RCUSAI Stock Diagnostic Report

Arcus Biosciences slides 20% on stock offering, kidney-cancer data

After the stock offering and renal cancer clinical data were released, Arcus Biosciences' stock price fell by 20%.

View Source Article ↗
AI CATALYST SCORE45 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

RCUS Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-10-22 03:44:42RCUS45MidView Report →
2026-10-21 22:17:06RCUS45MidView Report →
2026-09-16 15:39:40RCUS60MidView Report →
View Full History for RCUS (Blueprint) →